EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+28.55%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$833M
AUM Growth
+$833M
(+87%)
Cap. Flow
+$268M
Cap. Flow
% of AUM
32.24%
Top 10 Holdings %
Top 10 Hldgs %
55.79%
Holding
71
New
22
Increased
19
Reduced
14
Closed
11
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$58.8M |
| 2 |
AstraZeneca
AZN
|
$39.6M |
| 3 |
United Therapeutics
UTHR
|
$33M |
| 4 |
GSK
GSK
|
$32.8M |
| 5 |
Envista
NVST
|
$29.1M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$18.7M |
| 2 |
Fate Therapeutics
FATE
|
$12.3M |
| 3 |
HSKA
Heska Corp
HSKA
|
$12M |
| 4 |
OraSure Technologies
OSUR
|
$11.4M |
| 5 |
Standard BioTools
LAB
|
$9.68M |
Sector Composition
| 1 | Healthcare | 98.78% |
| 2 | Financials | 0.05% |
| 3 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMRN
1
Amarin Corp
AMRN
$311M
| $78M | 9.15% | 15,943,915 +5,290,456 | +50% | +$25.9M |
|
|
2
United Therapeutics
UTHR
$13.8B
| $69.6M | 8.17% | 458,636 +217,732 | +90% | +$33M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $58.8M | 6.89% | +376,200 | New | +$58.8M |
|
4
TG Therapeutics
TGTX
$4.65B
| $44.9M | 5.27% | 863,851 -159,479 | -16% | -$8.3M |
|
|
5
AstraZeneca
AZN
$248B
| $42.6M | 5% | 852,431 +791,495 | +1,299% | +$39.6M |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $38.8M | 4.56% | 530,976 -76,781 | -13% | -$5.62M |
|
|
7
Fate Therapeutics
FATE
$120M
| $36.3M | 4.26% | 399,499 -135,537 | -25% | -$12.3M |
|
|
8
GSK
GSK
$79.9B
| $35.2M | 4.13% | 946,581 +882,209 | +1,370% | +$32.8M |
|
9
Ascendis Pharma
ASND
$11.8B
| $31.2M | 3.66% | 187,043 +26,039 | +16% | +$4.34M |
|
|
CTLT
10
DELISTED
CATALENT, INC.
CTLT
| $29.1M | 3.41% | 279,503 +139,174 | +99% | +$14.5M |
|
|
11
Envista
NVST
$3.52B
| $29.1M | 3.41% | +861,355 | New | +$29.1M |
|
12
Danaher
DHR
$147B
| $28.1M | 3.29% | 126,330 +94,970 | +303% | +$21.1M |
|
13
Teva Pharmaceuticals
TEVA
$21.1B
| $26.5M | 3.11% | 2,748,250 +353,895 | +15% | +$3.42M |
|
14
Avantor
AVTR
$9.18B
| $25.9M | 3.04% | +920,650 | New | +$25.9M |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $23.6M | 2.77% | 138,644 +136,747 | +7,209% | +$23.3M |
|
16
Elevance Health
ELV
$71.8B
| $21.1M | 2.48% | +65,771 | New | +$21.1M |
|
|
ZGNX
17
DELISTED
Zogenix, Inc.
ZGNX
| $18.2M | 2.13% | 909,708 +44,467 | +5% | +$889K |
|
18
Qiagen
QGEN
$10.1B
| $17.8M | 2.09% | 336,862 +169,389 | +101% | +$8.95M |
|
19
The Ensign Group
ENSG
$9.91B
| $15.2M | 1.78% | 208,470 -110,393 | -35% | -$8.06M |
|
|
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $14.1M | 1.65% | 246,240 -156,193 | -39% | -$8.91M |
|
|
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.3M | 1.33% | 356,235 +179,477 | +102% | +$5.71M |
|
|
TARO
22
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $11.2M | 1.31% | 152,256 +10,367 | +7% | +$761K |
|
|
HSKA
23
DELISTED
Heska Corp
HSKA
| $11.1M | 1.3% | 76,166 -82,606 | -52% | -$12M |
|
|
KDMN
24
DELISTED
Kadmon Holdings, Inc.
KDMN
| $10M | 1.17% | +2,408,885 | New | +$10M |
|
|
BHVN
25
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $8.89M | 1.04% | 103,764 -217,817 | -68% | -$18.7M |
|